- Không có dữ liệu
Tiếng Việt
- English
- 简体中文
- 繁体中文
- Français
- Русский
- Italiano
- 日本語
- 한국어
- Português
- Deutsch
- Español
- Türkçe
- Ελληνικά
- Nederlands
- Tiếng Việt
- Polski
Rocket Lab USA continues its path of vertical integration and has signed an exclusive but non binding agreement with MynaricAG, a German laser communication terminal (LCT) supplier and Rocket Lab supplier, to acquire the company for $75 million in cash or stock.If Mynaric achieves its revenue target, it will pay an additional revenue of up to $75 million. This acquisition depends on whether Myna...
Researchers at the Federal College of Technology in Lausanne (EPFL) have shown that femtosecond lasers suitable for palm size can be manufactured using glass substrates.Can femtosecond lasers made entirely of glass become a reality? This interesting question prompted Yves Bellouard, the head of the Galata laboratory at the Federal Institute of Technology in Lausanne, to embark on a journey after y...
In recent years, the performance of Chinese laser technology enterprises in the international market has become increasingly eye-catching. On September 20th, under the joint witness of nearly a hundred customer representatives from various industries in South Korea, the opening ceremony of Zhuolai Laser South Korea Branch was officially held.The branch is located in the Gyeonggi do region of south...
Driven by the global trend of lightweighting in new energy vehicles (NEVs), TRUMPF has reached a significant milestone in Taicang, Jiangsu—the successful rollout of the 100th TruLaser Cell series 3D five-axis laser cutting machine. This achievement is more than just a numerical breakthrough; it symbolizes the deep integration of German technology with Chinese manufacturing and underscores TRUMPF's...
On July 3rd local time, Swiss ophthalmic care giant Alcon announced the acquisition of Israeli medical technology company Belkin Vision and its laser equipment assets for treating glaucoma.The transaction includes a prepayment of $81 million, of which approximately $65 million is in cash. In addition, if Alcon can establish this technology as the preferred first-line treatment option for clinical ...